-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IIkQEvq27x4B1nmzx7Yq3HcHKfJHJtP7CHAz+rF2YdQ1tafglQ5CRwsw0LEDcu4S MGiIPnosWr2UK9vX2Uv6HQ== 0001193805-07-002143.txt : 20070817 0001193805-07-002143.hdr.sgml : 20070817 20070817172016 ACCESSION NUMBER: 0001193805-07-002143 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070803 FILED AS OF DATE: 20070817 DATE AS OF CHANGE: 20070817 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE ACQUISITION CORP CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2116 FINANCIAL CENTER STREET 2: 666 WALNUT STREET CITY: DES MOINES STATE: IA ZIP: 50309 BUSINESS PHONE: 515-244-5746 MAIL ADDRESS: STREET 1: 2116 FINANCIAL CENTER STREET 2: 666 WALNUT STREET CITY: DES MOINES STATE: IA ZIP: 50309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WRIGHT DAVID P CENTRAL INDEX KEY: 0001206342 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 071065956 BUSINESS ADDRESS: STREET 1: 6611 TRIBUTARY STREET STREET 2: C/O GUILFORD PHARMACEUTICALS INC CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: 4106316300 MAIL ADDRESS: STREET 1: C/O GUILFORD PHARMACEUTICALS INC STREET 2: 6611 TIBUTARY ST. CITY: BALTIMORE STATE: MD ZIP: 21224 4/A 1 e602456_ex.xml FORM 4/A X0202 4/A 2007-08-03 2007-08-08 0 0001326190 HEALTHCARE ACQUISITION CORP PIP 0001206342 WRIGHT DAVID P C/O PHARMATHENE, INC. ONE PARK PLACE, SUITE 450 ANNAPOLIS MD 21401 1 1 0 1 Chief Executive Officer Member of Section 13(d) Group Common Stock, $0.0001 par value per share 2007-08-03 4 J 0 50542 A 100542 D Common Stock, $0.0001 par value per share 2007-08-10 4 J 0 1274 A 101816 D Stock Option (right to buy) 3.28 2007-08-03 4 A 0 52044 A 2003-07-15 2013-07-15 Common Stock 52044 52044 D Stock Option (right to buy) 4.22 2007-08-03 4 A 0 41006 A 2005-01-18 2015-01-18 Common Stock 41006 41006 D Stock Option (right to buy) 4.22 2007-08-03 4 A 0 6420 A 2006-01-01 2016-01-01 Common Stock 6420 6420 D Stock Option (right to buy) 4.22 2007-08-03 4 A 0 4063 A 2007-01-04 2017-01-04 Common Stock 4063 4063 D Unsecured Convertible Note 10 2007-08-03 4 A 0 5313 A 2007-08-03 2009-08-03 Common Stock 5313 5313 D Pursuant to the Agreement and Plan of Merger, dated as of January 19, 2007, the Issuer, PAI Acquisition Corp., a Delaware Corporation and a direct wholly-owned subsidiary of the Issuer ("Merger Sub"), and PharmAthene, Inc., a privately held Delaware corporation ("Target"), Merger Sub merged with and into Target as a result of which Target became a wholly-owned subsidiary of the Issuer (the "Merger"). Received in the Merger in exchange for 1,015,520 shares of Target common stock. The merger agreement provides that the former stockholders of Target may receive additional shares of the Issuer common stock if holders of more than 5% of the Issuer common stock exercise their conversion rights which was to be determined within 3 business days following the effective date of the merger (8/8/07) (the "Adjustment Shares"). The Reporting Person's right to receive a pro rata portion of the Adjustment Shares pursuant to this right became fixed and irrevocable on August 3, 2007, the effective date of the merger. The calculation of the Adjustment Shares issuable was finalized on August 9, 2007. See Note 4 below. On August 3, 2007, the effective date of the Merger, the closing price of the Issuer's common stock was $6.16 per share. On August 9, 2007, the pro rata portion of the Adjustment Shares to be received by the Reporting Person was determined. Received in the Merger in exchange for 2,284,326 stock options of the Target, issuable upon exercise. Received in the Merger in exchange for a convertible note of the Target in the principal amount of $50,000 (plus accrued interest). Immediately convertible into shares of common stock of Issuer at the rate of $10 per share. This amendment is being filed to reflect the issuance of the Adjustment Shares noted in Notes 2 and 4 above. /s/ David P. Wright 2007-08-17 -----END PRIVACY-ENHANCED MESSAGE-----